Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CL-H1T in Acute Migraine Pain
NCT03877718Phase 2Completed
- Sponsor
- Charleston Laboratories, Inc.
- Start
- Feb 2019
- Primary completion
- Aug 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sumatriptan + promethazine in migraine (6 arms), sponsored by Charleston Laboratories, Inc. Primary endpoints: Percentage of subjects who are pain-free 2 hours after taking investigational treatment and Percentage of subjects who are nausea-free 2 hours after taking investigational treatment. Started Feb 2019; status: completed.
02
Drugs
sumatriptan + promethazine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03877718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877718.